Cristian Cuevas
Psychiatric/Mental Health · Anaheim, CANPI 1013796200
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 160 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 31.8% of the total. Reporting peaked in 2024 at $2,391 and has fallen 55.4% since, to $1,067 in 2025. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $26.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$650
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$635
- Alkermes, Inc.$249
- Otsuka America Pharmaceutical, Inc.$245
- Neurocrine Biosciences, Inc.$230
- plus $894 from 11 others
What the payments were for
- Food & beverage$4,244100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 56 | $1,353 |
| Johnson & Johnson | 21 | $650 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $635 |
| Alkermes, Inc. | 6 | $249 |
| Otsuka America Pharmaceutical, Inc. | 11 | $245 |
| Neurocrine Biosciences, Inc. | 8 | $230 |
| Teva Pharmaceuticals USA, Inc. | 6 | $229 |
| Tris Pharma Inc | 5 | $176 |
| Almatica Pharma LLC | 5 | $131 |
| Lundbeck LLC | 5 | $100 |
| Tempus AI, Inc | 4 | $72 |
| Vanda Pharmaceuticals Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Corium, LLC | 1 | $32 |
| Biogen | 1 | $29 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$520
- CAPLYTA$383
- VRAYLAR$250
- ARISTADA INITIO$130
- Dyanavel XR$125
- Quillivant$125
- Quillichew ER$125
- Austedo XR$125
- INVEGA SUSTENNA$124
- INVEGA TRINZA$124
How this compares
$4,256 in reported general payments places this provider in the 90th percentile of 2,433 psychiatric/mental health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 13 | $76 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Anaheim
- Samantha PerkinsAnaheim$49K
- Vanessa YanAnaheim$26K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.